Global Drugs for Schistosomiasis Market Overview And Scope:
Global Drugs for Schistosomiasis Market Size was estimated at USD 82.13 million in 2022 and is projected to reach USD 102.95 million by 2028, exhibiting a CAGR of 3.84% during the forecast period.
The Global Drugs for Schistosomiasis Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Drugs for Schistosomiasis utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Shin Poong, Merck, Bayer, EIPICO, Chandra Bhagat Pharma, Taj Pharmaceuticals
Global Drugs for Schistosomiasis Market Segmentation
By Type, Drugs for Schistosomiasis market has been segmented into:Praziquantel
Oxamniquine
Other
By Application, Drugs for Schistosomiasis market has been segmented into:
S. haematobium
S. mansoni
S. japonicum
S. mekongi
S. intercalatum
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Drugs for Schistosomiasis market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Drugs for Schistosomiasis market.
Top Key Players Covered in Drugs for Schistosomiasis market are:
Shin Poong
Merck
Bayer
EIPICO
Chandra Bhagat Pharma
Taj Pharmaceuticals
Objective to buy this Report:
1. Drugs for Schistosomiasis analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Drugs for Schistosomiasis market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Drugs for Schistosomiasis Market by Type
5.1 Drugs for Schistosomiasis Market Overview Snapshot and Growth Engine
5.2 Drugs for Schistosomiasis Market Overview
5.3 Praziquantel
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Praziquantel: Geographic Segmentation
5.4 Oxamniquine
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Oxamniquine: Geographic Segmentation
5.5 Other
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Other: Geographic Segmentation
Chapter 6: Drugs for Schistosomiasis Market by Application
6.1 Drugs for Schistosomiasis Market Overview Snapshot and Growth Engine
6.2 Drugs for Schistosomiasis Market Overview
6.3 S. haematobium
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 S. haematobium: Geographic Segmentation
6.4 S. mansoni
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 S. mansoni: Geographic Segmentation
6.5 S. japonicum
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 S. japonicum: Geographic Segmentation
6.6 S. mekongi
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 S. mekongi: Geographic Segmentation
6.7 S. intercalatum
6.7.1 Introduction and Market Overview
6.7.2 Historic and Forecasted Market Size (2017-2032F)
6.7.3 Key Market Trends, Growth Factors and Opportunities
6.7.4 S. intercalatum: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Drugs for Schistosomiasis Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Drugs for Schistosomiasis Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Drugs for Schistosomiasis Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 SHIN POONG
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 MERCK
7.4 BAYER
7.5 EIPICO
7.6 CHANDRA BHAGAT PHARMA
7.7 TAJ PHARMACEUTICALS
Chapter 8: Global Drugs for Schistosomiasis Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Praziquantel
8.2.2 Oxamniquine
8.2.3 Other
8.3 Historic and Forecasted Market Size By Application
8.3.1 S. haematobium
8.3.2 S. mansoni
8.3.3 S. japonicum
8.3.4 S. mekongi
8.3.5 S. intercalatum
Chapter 9: North America Drugs for Schistosomiasis Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Praziquantel
9.4.2 Oxamniquine
9.4.3 Other
9.5 Historic and Forecasted Market Size By Application
9.5.1 S. haematobium
9.5.2 S. mansoni
9.5.3 S. japonicum
9.5.4 S. mekongi
9.5.5 S. intercalatum
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Drugs for Schistosomiasis Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Praziquantel
10.4.2 Oxamniquine
10.4.3 Other
10.5 Historic and Forecasted Market Size By Application
10.5.1 S. haematobium
10.5.2 S. mansoni
10.5.3 S. japonicum
10.5.4 S. mekongi
10.5.5 S. intercalatum
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Drugs for Schistosomiasis Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Praziquantel
11.4.2 Oxamniquine
11.4.3 Other
11.5 Historic and Forecasted Market Size By Application
11.5.1 S. haematobium
11.5.2 S. mansoni
11.5.3 S. japonicum
11.5.4 S. mekongi
11.5.5 S. intercalatum
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Drugs for Schistosomiasis Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Praziquantel
12.4.2 Oxamniquine
12.4.3 Other
12.5 Historic and Forecasted Market Size By Application
12.5.1 S. haematobium
12.5.2 S. mansoni
12.5.3 S. japonicum
12.5.4 S. mekongi
12.5.5 S. intercalatum
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Drugs for Schistosomiasis Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Praziquantel
13.4.2 Oxamniquine
13.4.3 Other
13.5 Historic and Forecasted Market Size By Application
13.5.1 S. haematobium
13.5.2 S. mansoni
13.5.3 S. japonicum
13.5.4 S. mekongi
13.5.5 S. intercalatum
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Drugs for Schistosomiasis Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Praziquantel
14.4.2 Oxamniquine
14.4.3 Other
14.5 Historic and Forecasted Market Size By Application
14.5.1 S. haematobium
14.5.2 S. mansoni
14.5.3 S. japonicum
14.5.4 S. mekongi
14.5.5 S. intercalatum
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Drugs for Schistosomiasis Scope:
|
Report Data
|
Drugs for Schistosomiasis Market
|
|
Drugs for Schistosomiasis Market Size in 2025
|
USD XX million
|
|
Drugs for Schistosomiasis CAGR 2025 - 2032
|
XX%
|
|
Drugs for Schistosomiasis Base Year
|
2024
|
|
Drugs for Schistosomiasis Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Shin Poong, Merck, Bayer, EIPICO, Chandra Bhagat Pharma, Taj Pharmaceuticals.
|
|
Key Segments
|
By Type
Praziquantel
Oxamniquine
Other
By Applications
S. haematobium
S. mansoni
S. japonicum
S. mekongi
S. intercalatum
|
